Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Refreshes Board with Appointment of Three New Directors
Adds Industry, Business Development and Financial Expertise NEW YORK , July 14, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the appointment of
View HTML
Toggle Summary Predictive Oncology Completes Acquisition of Quantitative Medicine
Acquisition Focused on Accelerating Commercialization of AI-driven Drug Discovery and Development MINNEAPOLIS , July 07, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug
View HTML
Toggle Summary Predictive Oncology Inc. Announces Receipt of Cash Proceeds of $2.2 Million from Exercise of Warrants
MINNEAPOLIS , June 29, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (the “Company,” “ Predictive Oncology,” “we,” “our” or “us”) (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced the
View HTML
Toggle Summary Predictive Oncology’s TumorGenesis Division Secures First Commercial Sale of its Novel Ovarian Cancer Cell Media
A Top US Medical Institution Places the First Commercial Order for the Media used to grow Ovarian Cancer Cell Types that are Exceedingly Difficult to Grow and Retain the Signatures of the Patient Derived Sample. MINNEAPOLIS , June 18, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc.
View HTML
Toggle Summary Predictive Oncology Reports First Quarter 2020 Financial Results, Provides Business Update
CancerQuest 2020 Study on Schedule for Completion in Q2 2020 NEW YORK , June 08, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today reported financial results
View HTML
Toggle Summary Predictive Oncology Completes Acquisition of Soluble Therapeutics and BioDtech
MINNEAPOLIS , June 02, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (the “Company”) a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the acquisition of the assets of Soluble
View HTML
Toggle Summary Predictive Oncology (NASDAQ Symbol POAI) is licensing and partnering this groundbreaking NSP10 technology in the race to develop a vaccine for development
MINNEAPOLIS , May 14, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI)  has, with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr.
View HTML
Toggle Summary Predictive Oncology Announces $2.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
MINNEAPOLIS , May 07, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into
View HTML
Toggle Summary Predictive Oncology and Dr. Daniel Carter Collaborating to Develop a Potential COVID-19 Vaccine Utilizing Novel Nanoparticle Vaccine Platform, Based on NSP-10
MINNEAPOLIS , May 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) has, with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr.
View HTML
Toggle Summary Predictive Oncology Exchanges $2.1 Million of Debt for Equity, Streamlining Capital Structure and Simplifying Balance Sheet
CEO Agrees to Exchange $2.1 Million Promissory Note for Newly Issued Equity, Demonstrating Confidence in Company’s Future NEW YORK , April 22, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced that it has entered into an Exchange Agreement relating to a $2.1 million
View HTML